CD38 and acute lymphoblastic leukemia: Nowadays, preclinical trials show that CD38 is highly expressed at both diagnosis and relapse steps in many pediatric hematological malignancies, with a strong expression in ALL; therefore, novel studies are highlighting the therapeutic role of CD38-targeting monoclonal antibodies, such as daratumumab and isatuximab, in pediatric hematological malignancies like ALL [153].